Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally ...
Treatment of Relapsed Wilms’ Tumor With High-Dose Therapy and Autologous Hematopoietic Stem-Cell Rescue: The Experience at Children’s Memorial Hospital Interleukin-12 (IL-12) and interferon alfa-2b ...
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...
The new presentation is expected to provide an additional self-administration option for patients with polycythemia vera.
Propensity score–matched VISION data showed no incremental 48-week HBsAg loss benefit from adding NAs to Peg-IFNα-2b, despite slightly lower HBV DNA in the combination arm. Baseline HBsAg strongly ...
Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...
Molecular response to therapy in early-stage PV patients correlates with improved event-free survival outcomes. Ropeginterferon alfa-2b significantly reduces JAK2V617F variant allele frequency, ...
A Prescription Drug User Fee Act target date of August 30, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results